Clinical Trial: Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
Study Status: Completed
Recruit Status: RECRUITING
Condition: Alcohol Abuse
Study Type: INTERVENTIONAL
Official Title: Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
Brief Summary:
This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of the GLP-1 receptor agonist semaglutide s.c.vs placebo on alcohol consumption in 108 patients diagnosed with alcohol use disorder and comorbid obesity (BMI>30 kg/m2).Patients will be treated for 26 weeks with semaglutide subcutaneously (s.c.) once weekly or placebo.The medication will be provided as a supplement to standardised cognitive behavioural therapy.A subgroup of the patients will have two brain scans…
Read more